BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 26, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» Kalivir’s oncolytic immunotherapy VET3-TGI cleared by FDA to enter clinic for solid tumors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Kalivir’s oncolytic immunotherapy VET3-TGI cleared by FDA to enter clinic for solid tumors
July 1, 2024
No Comments
Kalivir Immunotherapeutics Inc. has announced FDA clearance of its IND application for VET3-TGI for patients with incurable, advanced solid tumors.
BioWorld Science
Regulatory
Cancer
Immuno-oncology
FDA
IND
